NEW YORK (GenomeWeb News) – Roche announced today that the US Food and Drug Administration has granted 510(k) clearance for four additional specimen types for use with the firm's cobas CT/NG v2.0 test, which helps physicians diagnose Chlamydia trachomatis and Neisseria gonorrhoeae infections in symptomatic and asymptomatic patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.